|Generex Makes Presentation Of Clinical Data On Generex Oral-lyn.|
|By Staff and Wire Reports|
|Friday, 16 September 2011 19:32|
Generex Biotechnology Corporation (OTC:GNBT) announced Dr. Nicola Napolii, from University Campus Bio-Medico in Rome, Italy, made a podium presentation of the clinical data on Generex Oral-lyn buccal insulin spray on September 14, 2011 at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.
Dr. Napoli presented a paper entitled Buccal spray insulin: a new tool to treat subjects with impaired glucose tolerance. The paper was authored by a team of investigators led by Professor Paolo Pozzilli of the Endocrinology & Diabetes Department of University Campus Bio-Medico and the Diabetes Department of Hospital "S. Pertini", both in Rome, Italy. The results reported in the scientific paper demonstrated that patients treated with Generex Oral-lyn achieved a significant reduction of HbA1c compared to the control group, with no adverse events.
Also, there was no significant difference in body weight and no hypoglycaemic or other adverse events were observed during the study period in both groups. These preliminary results suggest that the addition of Generex Oral-lyn can be an effective treatment compared to diet and physical exercise alone in patients with impaired glucose tolerance (IGT) in reducing HbA1c without adverse effects.
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2011 UBS Global Life Sciences Conference in New York.
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a 102 week Phase III study for linagliptin (trade name Trajenta® in Europe), which show meaningful and durable reductions in blood glucose for adults with type 2 diabetes (T2D).
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA™ (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to provide an update for the rollout of its co-branded alliance with Prescription Vending Machines Inc. (DBA Medicine Dispensing Systems) (“PVM”) to distribute PVM’s MedBoxTM.
Eli Lilly and Company (NYSE: LLY) has once again been selected one of the "100 Best Companies" by Working Mother magazine. This is the 17th consecutive year for this honor.
Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced today that its presentation at the UBS Global Life Sciences Conference to be held on September 19-21, 2011 at the Grand Hyatt Hotel in New York has been rescheduled to a different time.
Fluidigm Corporation (NASDAQ:FLDM) today announced that Director of Strategic Marketing Un Kwon-Casado will present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011 at the Grand Hyatt, New York City, beginning at 8:00 a.m. Eastern Time.
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that the company will make a presentation at the UBS Global Life Sciences Conference in New York on Tuesday, September 20, 2011 at 9:30 a.m. Eastern Time.
Palomar Medical Technologies, Inc. (NASDAQ: PMTI), a leading researcher and developer of light-based systems for aesthetic treatments, and Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, today announced that they have entered into a comprehensive settlement agreement ending the patent disputes between the companies on mutually agreeable terms.
Pathfinder Cell Therapy, Inc. (OTCQB: PFND), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that effective at the start of trading today, the ticker symbol for its common stock will change from SYMD to PFND.
Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that it and its five wholly-owned subsidiaries, Provectus Biotech, Inc., a Tennessee corporation, Provectus Devicetech, Inc., a Tennessee corporation, Provectus Imaging, Inc., a Tennessee corporation, Pure-ific Corporation, a Nevada corporation, and Xantech Pharmaceuticals, Inc., a Tennessee corporation (collectively, the “Subsidiaries”), are making an unregistered offering of Units pursuant to the exemption from registration requirements under Rule 506 of Regulation D and Section 4(2) of the Securities Act of 1933, as amended (the “Act”).
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, announced today that an overview of the Company’s business strategy will be given at the UBS Global Life Sciences Conference, being held at the Grand Hyatt Hotel in New York City.
Vantage Health (OTCBB:VNTH), (the "Company") announces that the Tanzania Food and Drugs Authority has today issued the Company's Tanzanian subsidiary, Vantage Health Tanzania Limited ("VHTL") with all necessary licensing, permitting and registration certificates, all of which became effective in August 2011, and which will further allow VHTL to expand its business in the healthcare field in Tanzania, including both pharmaceutical wholesale and pharmaceutical retail.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex will webcast its presentation at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011 at 1:00 p.m. EDT and at the Sixth Annual JMP Securities Healthcare Conference on Tuesday, September 27, 2011 at 1:00 p.m. EDT.
VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal.